Free Trial

Semler Scientific (SMLR) Financials

Semler Scientific logo
$34.26 +0.50 (+1.48%)
As of 04/14/2025 04:00 PM Eastern
Annual Income Statements for Semler Scientific

Annual Income Statements for Semler Scientific

This table shows Semler Scientific's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
14 21 41
Consolidated Net Income / (Loss)
14 21 41
Net Income / (Loss) Continuing Operations
14 21 41
Total Pre-Tax Income
18 24 48
Total Operating Income
17 22 21
Total Gross Profit
52 61 52
Total Revenue
57 68 56
Operating Revenue
57 68 56
Total Cost of Revenue
4.25 6.98 4.76
Operating Cost of Revenue
4.25 6.98 4.76
Total Operating Expenses
35 39 31
Selling, General & Admin Expense
13 14 13
Marketing Expense
18 18 13
Research & Development Expense
4.81 5.77 4.79
Restructuring Charge
0.00 0.73 0.00
Total Other Income / (Expense), net
0.49 1.84 27
Interest & Investment Income
0.49 2.47 1.88
Other Income / (Expense), net
-0.01 -0.63 25
Income Tax Expense
3.37 3.52 6.99
Basic Earnings per Share
$2.13 $3.06 $5.66
Weighted Average Basic Shares Outstanding
6.73M 6.73M 7.23M
Diluted Earnings per Share
$1.79 $2.63 $5.13
Weighted Average Diluted Shares Outstanding
8.00M 7.82M 7.98M
Weighted Average Basic & Diluted Shares Outstanding
6.84M 7.03M 9.60M

Quarterly Income Statements for Semler Scientific

This table shows Semler Scientific's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
3.68 3.22 4.97 5.88 5.51 4.22 6.07 0.01 5.61 29
Consolidated Net Income / (Loss)
3.68 3.22 4.97 5.88 5.51 4.22 6.07 0.01 5.61 29
Net Income / (Loss) Continuing Operations
3.68 3.22 4.97 5.88 5.51 4.22 6.07 0.01 5.61 29
Total Pre-Tax Income
4.60 3.96 6.63 7.67 6.99 2.81 7.80 1.14 6.38 33
Total Operating Income
4.47 3.62 6.26 7.18 6.30 2.52 6.98 5.35 5.07 3.54
Total Gross Profit
13 13 17 17 15 12 15 13 12 11
Total Revenue
14 14 18 19 16 15 16 14 14 12
Operating Revenue
14 14 18 19 16 15 16 14 14 12
Total Cost of Revenue
1.14 1.18 1.27 1.22 1.11 3.39 1.25 1.26 1.16 1.10
Operating Cost of Revenue
1.14 1.18 1.27 1.22 1.11 3.39 1.25 1.26 1.16 1.10
Total Operating Expenses
8.44 9.00 11 10 8.91 9.15 7.68 7.86 7.29 7.77
Selling, General & Admin Expense
3.05 2.98 3.86 3.46 3.71 3.26 2.87 2.96 3.13 3.77
Marketing Expense
4.15 4.66 5.19 4.99 3.42 4.55 3.68 3.46 2.98 2.97
Research & Development Expense
1.24 1.37 1.63 1.76 1.17 1.21 1.14 1.44 1.19 1.03
Total Other Income / (Expense), net
0.13 0.34 0.38 0.49 0.69 0.29 0.82 -4.21 1.31 29
Interest & Investment Income
- - 0.48 0.60 0.69 0.70 0.82 0.71 0.17 0.18
Other Income / (Expense), net
-0.00 -0.00 -0.11 -0.11 -0.00 -0.41 0.00 -4.93 1.14 29
Income Tax Expense
0.93 0.74 1.66 1.79 1.47 -1.41 1.72 1.13 0.77 3.37
Basic Earnings per Share
$0.55 $0.48 $0.74 $0.88 $0.82 $0.62 $0.88 $0.00 $0.80 $3.98
Weighted Average Basic Shares Outstanding
6.68M 6.73M 6.70M 6.71M 6.72M 6.73M 6.89M 6.94M 7.05M 7.23M
Diluted Earnings per Share
$0.46 $0.41 $0.63 $0.75 $0.71 $0.54 $0.78 $0.00 $0.72 $3.63
Weighted Average Diluted Shares Outstanding
7.94M 8.00M 7.90M 7.87M 7.82M 7.82M 7.78M 7.80M 7.77M 7.98M
Weighted Average Basic & Diluted Shares Outstanding
6.84M 6.84M 6.85M 6.86M 6.87M 7.03M 7.07M 7.13M 7.27M 9.60M

Annual Cash Flow Statements for Semler Scientific

This table details how cash moves in and out of Semler Scientific's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents
-14 34 -48
Net Cash From Operating Activities
17 21 24
Net Cash From Continuing Operating Activities
17 21 24
Net Income / (Loss) Continuing Operations
14 21 41
Consolidated Net Income / (Loss)
14 21 41
Depreciation Expense
0.59 0.60 0.58
Non-Cash Adjustments To Reconcile Net Income
1.23 4.55 -24
Changes in Operating Assets and Liabilities, net
1.32 -4.40 6.92
Net Cash From Investing Activities
-27 18 -190
Net Cash From Continuing Investing Activities
-27 18 -190
Purchase of Property, Plant & Equipment
-2.16 -0.35 -0.05
Purchase of Investments
-20 -59 -0.50
Sale and/or Maturity of Investments
-4.68 78 0.00
Other Investing Activities, net
0.00 -0.48 -189
Net Cash From Financing Activities
-4.94 -5.41 117
Net Cash From Continuing Financing Activities
-4.94 -5.41 117
Repurchase of Common Equity
-4.99 -1.95 -3.00
Issuance of Common Equity
- 0.00 120
Other Financing Activities, net
0.05 -3.46 0.59
Cash Income Taxes Paid
2.40 4.06 2.26

Quarterly Cash Flow Statements for Semler Scientific

This table details how cash moves in and out of Semler Scientific's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
5.51 -23 -18 34 -2.00 20 5.55 -55 -0.76 2.25
Net Cash From Operating Activities
8.02 1.71 0.86 11 4.83 4.44 5.62 4.93 6.43 7.43
Net Cash From Continuing Operating Activities
8.02 1.71 0.86 11 4.83 4.44 5.62 4.93 6.43 7.43
Net Income / (Loss) Continuing Operations
3.68 3.22 4.97 5.88 5.51 4.22 6.07 0.01 5.61 29
Consolidated Net Income / (Loss)
3.68 3.22 4.97 5.88 5.51 4.22 6.07 0.01 5.61 29
Depreciation Expense
0.15 0.13 0.13 0.15 0.16 0.16 0.18 0.17 0.13 0.10
Non-Cash Adjustments To Reconcile Net Income
0.14 0.17 0.63 0.42 0.50 3.00 0.16 5.34 -0.91 -29
Changes in Operating Assets and Liabilities, net
4.06 -1.80 -4.87 4.75 -1.34 -2.94 -0.79 -0.58 1.59 6.70
Net Cash From Investing Activities
-0.49 -24 -18 25 -6.78 19 -0.08 -60 -8.44 -121
Net Cash From Continuing Investing Activities
-0.49 -24 -18 25 -6.78 19 -0.08 -60 -8.44 -121
Purchase of Property, Plant & Equipment
-0.49 -0.81 -0.64 -0.30 -0.15 0.74 -0.08 0.03 -0.04 0.03
Other Investing Activities, net
- - - - - -0.48 - - -8.40 -121
Net Cash From Financing Activities
-2.03 0.08 -0.15 -1.98 -0.05 -3.24 0.01 0.11 1.25 116
Net Cash From Continuing Financing Activities
-2.03 0.08 -0.15 -1.98 -0.05 -3.24 0.01 0.11 1.25 116
Repurchase of Common Equity
-2.05 - - - - - - - -0.49 -2.41
Issuance of Common Equity
- - - - - - - - - 117
Other Financing Activities, net
0.02 0.08 -0.15 -0.03 -0.05 -3.24 0.01 0.21 -0.80 1.17

Annual Balance Sheets for Semler Scientific

This table presents Semler Scientific's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets
63 78 240
Total Current Assets
49 66 23
Cash & Equivalents
23 57 8.82
Restricted Cash
0.00 0.13 0.13
Note & Lease Receivable
- 0.00 6.10
Accounts Receivable
3.88 6.13 4.38
Inventories, net
0.47 0.45 0.36
Prepaid Expenses
1.47 2.04 2.90
Plant, Property, & Equipment, net
2.48 3.01 1.91
Total Noncurrent Assets
11 9.12 215
Long-Term Investments
0.82 0.51 0.51
Noncurrent Note & Lease Receivables
4.68 5.37 0.00
Intangible Assets
- 0.00 215
Noncurrent Deferred & Refundable Income Taxes
2.30 2.96 0.00
Other Noncurrent Operating Assets
3.51 0.27 0.09
Total Liabilities & Shareholders' Equity
63 78 240
Total Liabilities
7.02 6.27 9.08
Total Current Liabilities
6.86 6.20 6.31
Accounts Payable
0.84 0.40 0.14
Accrued Expenses
4.75 4.50 5.17
Current Deferred Revenue
1.16 1.12 0.77
Other Current Liabilities
0.11 0.18 0.23
Total Noncurrent Liabilities
0.16 0.07 2.77
Noncurrent Deferred & Payable Income Tax Liabilities
- 0.00 2.77
Other Noncurrent Operating Liabilities
0.16 0.07 0.00
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
56 72 231
Total Preferred & Common Equity
56 72 231
Total Common Equity
56 72 231
Common Stock
16 12 130
Retained Earnings
39 60 101

Quarterly Balance Sheets for Semler Scientific

This table presents Semler Scientific's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
61 70 75 79 84 85 92
Total Current Assets
52 56 61 64 72 24 21
Cash & Equivalents
46 5.31 39 37 63 7.33 6.57
Restricted Cash
- - - - 0.13 0.13 0.13
Note & Lease Receivable
- - - - - 6.10 6.10
Accounts Receivable
3.67 9.34 6.03 5.97 6.13 7.47 6.67
Inventories, net
0.51 0.51 0.48 0.44 0.41 0.39 0.38
Prepaid Expenses
1.96 2.77 2.42 1.95 2.48 2.27 1.65
Plant, Property, & Equipment, net
2.62 3.58 3.69 3.26 0.00 2.39 1.74
Total Noncurrent Assets
6.62 11 11 12 11 59 69
Long-Term Investments
0.82 0.82 0.82 0.82 0.51 0.51 0.51
Noncurrent Note & Lease Receivables
1.18 5.07 4.96 5.46 7.44 0.00 0.00
Intangible Assets
- - - - - 55 64
Noncurrent Deferred & Refundable Income Taxes
2.35 2.38 2.51 2.78 3.10 3.12 3.32
Other Noncurrent Operating Assets
2.27 2.82 2.74 2.74 0.25 0.13 0.65
Total Liabilities & Shareholders' Equity
61 70 75 79 84 85 92
Total Liabilities
8.57 9.06 10 8.67 5.95 6.39 6.84
Total Current Liabilities
8.39 8.92 10 8.58 5.90 6.36 6.84
Accounts Payable
0.48 0.30 0.51 0.30 0.41 0.23 0.55
Accrued Expenses
6.65 7.21 8.24 7.00 4.31 5.09 5.26
Current Deferred Revenue
1.16 1.29 1.19 1.12 1.00 0.84 0.81
Other Current Liabilities
0.09 0.13 0.14 0.16 0.19 0.21 0.23
Total Noncurrent Liabilities
0.18 0.14 0.12 0.09 0.05 0.02 0.00
Other Noncurrent Operating Liabilities
0.18 0.14 0.12 0.09 0.05 0.02 0.00
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
52 61 65 71 78 78 85
Total Preferred & Common Equity
52 61 65 71 78 78 85
Total Common Equity
52 61 65 71 78 78 85
Common Stock
16 17 15 15 12 13 14
Retained Earnings
36 44 50 56 66 66 71

Annual Metrics and Ratios for Semler Scientific

This table displays calculated financial ratios and metrics derived from Semler Scientific's official financial filings.

Metric 2022 2023 2024
Growth Metrics
- - -
Revenue Growth
6.90% 20.28% -17.44%
EBITDA Growth
-11.39% 24.97% 109.58%
EBIT Growth
-11.56% 25.76% 112.71%
NOPAT Growth
-19.08% 36.46% -5.94%
Net Income Growth
-16.82% 43.69% 98.70%
EPS Growth
-15.57% 46.93% 95.06%
Operating Cash Flow Growth
8.76% 22.14% 14.44%
Free Cash Flow Firm Growth
-33.92% 75.92% -1,226.03%
Invested Capital Growth
58.96% 18.55% 1,486.17%
Revenue Q/Q Growth
4.14% 1.89% -4.48%
EBITDA Q/Q Growth
11.81% -6.19% 184.70%
EBIT Q/Q Growth
12.49% -6.48% 192.61%
NOPAT Q/Q Growth
11.45% 4.96% 2.25%
Net Income Q/Q Growth
13.55% 5.13% 157.00%
EPS Q/Q Growth
14.74% 5.20% 151.47%
Operating Cash Flow Q/Q Growth
0.30% 14.69% 13.93%
Free Cash Flow Firm Q/Q Growth
-30.53% 65.28% -305.42%
Invested Capital Q/Q Growth
96.30% 0.19% 183.18%
Profitability Metrics
- - -
Gross Margin
92.50% 89.76% 91.55%
EBITDA Margin
31.38% 32.60% 82.75%
Operating Margin
30.35% 32.64% 37.19%
EBIT Margin
30.34% 31.72% 81.73%
Profit (Net Income) Margin
25.27% 30.19% 72.65%
Tax Burden Percent
80.97% 85.41% 85.41%
Interest Burden Percent
102.87% 111.42% 104.08%
Effective Tax Rate
19.03% 14.59% 14.59%
Return on Invested Capital (ROIC)
145.31% 147.81% 15.20%
ROIC Less NNEP Spread (ROIC-NNEP)
144.35% 144.72% -53.20%
Return on Net Nonoperating Assets (RNNOA)
-117.01% -115.52% 11.84%
Return on Equity (ROE)
28.30% 32.29% 27.04%
Cash Return on Invested Capital (CROIC)
99.78% 130.84% -161.08%
Operating Return on Assets (OROA)
30.34% 30.73% 28.95%
Return on Assets (ROA)
25.27% 29.25% 25.73%
Return on Common Equity (ROCE)
28.30% 32.29% 27.04%
Return on Equity Simple (ROE_SIMPLE)
25.73% 28.67% 17.72%
Net Operating Profit after Tax (NOPAT)
14 19 18
NOPAT Margin
24.57% 27.88% 31.76%
Net Nonoperating Expense Percent (NNEP)
0.97% 3.10% 68.40%
Return On Investment Capital (ROIC_SIMPLE)
- 26.48% 7.75%
Cost of Revenue to Revenue
7.50% 10.24% 8.45%
SG&A Expenses to Revenue
22.47% 20.96% 22.62%
R&D to Revenue
8.48% 8.47% 8.51%
Operating Expenses to Revenue
62.15% 57.12% 54.36%
Earnings before Interest and Taxes (EBIT)
17 22 46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
18 22 47
Valuation Ratios
- - -
Price to Book Value (P/BV)
4.05 4.24 1.70
Price to Tangible Book Value (P/TBV)
4.05 4.24 24.35
Price to Revenue (P/Rev)
3.98 4.46 6.97
Price to Earnings (P/E)
15.76 14.79 9.59
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
6.35% 6.76% 10.42%
Enterprise Value to Invested Capital (EV/IC)
15.45 17.67 1.73
Enterprise Value to Revenue (EV/Rev)
3.21 3.62 6.80
Enterprise Value to EBITDA (EV/EBITDA)
10.22 11.09 8.22
Enterprise Value to EBIT (EV/EBIT)
10.57 11.40 8.32
Enterprise Value to NOPAT (EV/NOPAT)
13.05 12.97 21.42
Enterprise Value to Operating Cash Flow (EV/OCF)
10.41 11.56 15.69
Enterprise Value to Free Cash Flow (EV/FCFF)
19.01 14.65 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-0.81 -0.80 -0.22
Leverage Ratio
1.12 1.10 1.05
Compound Leverage Factor
1.15 1.23 1.09
Debt to Total Capital
0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
22.79 32.91 27.47
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
7.13 10.64 3.59
Quick Ratio
6.85 10.21 3.06
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
9.56 17 -189
Operating Cash Flow to CapEx
808.47% 6,182.61% 47,862.75%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00
Efficiency Ratios
- - -
Asset Turnover
1.00 0.97 0.35
Accounts Receivable Turnover
15.11 13.62 10.72
Inventory Turnover
8.35 15.28 11.85
Fixed Asset Turnover
25.11 24.87 22.91
Accounts Payable Turnover
6.65 11.29 17.56
Days Sales Outstanding (DSO)
24.16 26.79 34.05
Days Inventory Outstanding (DIO)
43.74 23.88 30.79
Days Payable Outstanding (DPO)
54.85 32.32 20.78
Cash Conversion Cycle (CCC)
13.04 18.35 44.06
Capital & Investment Metrics
- - -
Invested Capital
12 14 221
Invested Capital Turnover
5.91 5.30 0.48
Increase / (Decrease) in Invested Capital
4.37 2.18 207
Enterprise Value (EV)
182 247 383
Market Capitalization
226 304 392
Book Value per Share
$8.14 $10.45 $31.76
Tangible Book Value per Share
$8.14 $10.45 $2.22
Total Capital
56 72 231
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-44 -58 -9.46
Capital Expenditures (CapEx)
2.16 0.35 0.05
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-1.04 2.41 7.42
Debt-free Net Working Capital (DFNWC)
42 60 16
Net Working Capital (NWC)
42 60 16
Net Nonoperating Expense (NNE)
-0.40 -1.57 -23
Net Nonoperating Obligations (NNO)
-44 -58 -9.46
Total Depreciation and Amortization (D&A)
0.59 0.60 0.58
Debt-free, Cash-free Net Working Capital to Revenue
-1.83% 3.54% 13.19%
Debt-free Net Working Capital to Revenue
74.18% 87.62% 29.09%
Net Working Capital to Revenue
74.18% 87.62% 29.09%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$2.13 $3.06 $5.66
Adjusted Weighted Average Basic Shares Outstanding
6.73M 6.73M 7.23M
Adjusted Diluted Earnings per Share
$1.79 $2.63 $5.13
Adjusted Weighted Average Diluted Shares Outstanding
8.00M 7.82M 7.98M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
6.84M 7.03M 9.60M
Normalized Net Operating Profit after Tax (NOPAT)
14 20 18
Normalized NOPAT Margin
24.57% 28.80% 31.76%
Pre Tax Income Margin
31.21% 35.35% 85.06%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
34.84% 9.47% 7.34%

Quarterly Metrics and Ratios for Semler Scientific

This table displays calculated financial ratios and metrics derived from Semler Scientific's official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
0.40% 19.52% 29.89% 25.47% 16.15% 9.15% -12.65% -22.25% -17.19% -17.55%
EBITDA Growth
-14.72% 100.91% 53.23% 35.39% 39.83% -39.19% 13.95% -91.79% -1.78% 1,328.48%
EBIT Growth
-15.04% 112.09% 55.99% 36.52% 41.04% -41.48% 13.48% -94.02% -1.41% 1,431.87%
NOPAT Growth
-13.96% 94.56% 39.52% 35.50% 39.30% 28.72% 15.94% -99.06% -10.34% -16.05%
Net Income Growth
-11.45% 113.40% 47.89% 44.31% 50.04% 31.25% 22.22% -99.81% 1.72% 591.92%
EPS Growth
-9.80% 127.78% 53.66% 47.06% 54.35% 31.71% 23.81% -100.00% 1.41% 572.22%
Operating Cash Flow Growth
5.03% 3.20% -42.68% 79.71% -39.77% 159.77% 553.19% -55.93% 33.00% 67.20%
Free Cash Flow Firm Growth
125.79% -16.00% -146.49% -42.66% -161.20% 212.18% 448.26% -2,233.25% -1,919.17% -12,861.20%
Invested Capital Growth
-17.46% 58.96% 71.63% 28.51% 132.28% 18.55% -20.41% 458.15% 461.16% 1,486.17%
Revenue Q/Q Growth
-5.27% -1.79% 31.98% 2.19% -12.30% -7.72% 5.62% -9.04% -6.59% -8.13%
EBITDA Q/Q Growth
-13.41% -18.97% 67.82% 14.99% -10.57% -64.76% 214.46% -91.71% 969.31% 412.51%
EBIT Q/Q Growth
-13.79% -19.04% 70.14% 14.96% -10.94% -66.41% 229.93% -93.94% 1,367.38% 421.98%
NOPAT Q/Q Growth
-12.20% -17.63% 59.47% 17.49% -9.73% -23.89% 43.64% -99.05% 8,509.91% -28.74%
Net Income Q/Q Growth
-9.79% -12.49% 54.51% 18.31% -6.21% -23.45% 43.88% -99.82% 50,890.91% 420.70%
EPS Q/Q Growth
-9.80% -10.87% 53.66% 19.05% -5.33% -23.94% 44.44% -100.00% 0.00% 404.17%
Operating Cash Flow Q/Q Growth
28.75% -78.68% -49.65% 1,200.35% -56.85% -8.05% 26.61% -12.27% 30.22% 15.60%
Free Cash Flow Firm Q/Q Growth
2.42% -129.49% -80.94% 204.92% -209.32% 154.05% 461.71% -742.66% -3.48% -241.63%
Invested Capital Q/Q Growth
-38.94% 96.30% 47.96% -27.54% 10.37% 0.19% -0.66% 408.13% 10.96% 183.18%
Profitability Metrics
- - - - - - - - - -
Gross Margin
91.90% 91.44% 93.03% 93.45% 93.19% 77.52% 92.16% 91.32% 91.44% 91.13%
EBITDA Margin
32.87% 27.12% 34.48% 38.80% 39.57% 15.11% 44.99% 4.10% 46.93% 261.79%
Operating Margin
31.80% 26.21% 34.36% 38.59% 38.61% 16.74% 43.87% 36.99% 37.49% 28.53%
EBIT Margin
31.78% 26.20% 33.77% 38.00% 38.59% 14.05% 43.88% 2.92% 45.94% 260.99%
Profit (Net Income) Margin
26.16% 23.31% 27.29% 31.60% 33.80% 28.03% 38.19% 0.08% 41.51% 235.27%
Tax Burden Percent
79.87% 81.27% 74.91% 76.69% 78.91% 150.05% 77.89% 0.97% 87.98% 89.66%
Interest Burden Percent
103.07% 109.49% 107.87% 108.45% 110.99% 133.00% 111.74% 268.79% 102.71% 100.54%
Effective Tax Rate
20.13% 18.73% 25.09% 23.31% 21.09% -50.05% 22.11% 99.03% 12.02% 10.34%
Return on Invested Capital (ROIC)
208.57% 125.98% 113.73% 170.58% 204.68% 133.21% 143.96% 0.53% 42.23% 12.24%
ROIC Less NNEP Spread (ROIC-NNEP)
208.31% 125.31% 113.05% 169.78% 203.63% 132.35% 142.78% 0.67% 38.63% -65.10%
Return on Net Nonoperating Assets (RNNOA)
-179.65% -101.58% -84.88% -136.93% -170.68% -105.65% -110.68% -0.28% -15.85% 14.48%
Return on Equity (ROE)
28.92% 24.41% 28.85% 33.65% 34.00% 27.56% 33.28% 0.25% 26.38% 26.73%
Cash Return on Invested Capital (CROIC)
207.67% 99.78% 57.99% 123.93% 102.21% 130.84% 148.87% -96.22% -101.52% -161.08%
Operating Return on Assets (OROA)
30.92% 26.20% 32.72% 36.91% 36.80% 13.61% 37.51% 2.25% 31.55% 92.43%
Return on Assets (ROA)
25.45% 23.31% 26.44% 30.70% 32.23% 27.16% 32.65% 0.06% 28.51% 83.32%
Return on Common Equity (ROCE)
28.92% 24.41% 28.85% 33.65% 34.00% 27.56% 33.28% 0.25% 26.38% 26.73%
Return on Equity Simple (ROE_SIMPLE)
24.10% 0.00% 26.04% 27.18% 27.66% 0.00% 27.84% 20.18% 18.64% 0.00%
Net Operating Profit after Tax (NOPAT)
3.57 2.94 4.69 5.51 4.97 3.78 5.43 0.05 4.46 3.18
NOPAT Margin
25.40% 21.30% 25.74% 29.60% 30.46% 25.12% 34.17% 0.36% 32.98% 25.58%
Net Nonoperating Expense Percent (NNEP)
0.26% 0.68% 0.68% 0.80% 1.05% 0.86% 1.19% -0.13% 3.60% 77.35%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - 5.27% - - - 1.38%
Cost of Revenue to Revenue
8.10% 8.56% 6.97% 6.55% 6.81% 22.48% 7.84% 8.68% 8.56% 8.87%
SG&A Expenses to Revenue
21.68% 21.59% 21.20% 18.59% 22.74% 21.66% 18.03% 20.49% 23.16% 30.39%
R&D to Revenue
8.86% 9.89% 8.95% 9.47% 7.20% 8.02% 7.16% 9.96% 8.78% 8.28%
Operating Expenses to Revenue
60.10% 65.23% 58.67% 54.86% 54.58% 60.78% 48.29% 54.34% 53.96% 62.60%
Earnings before Interest and Taxes (EBIT)
4.46 3.61 6.15 7.07 6.30 2.12 6.98 0.42 6.21 32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
4.62 3.74 6.28 7.22 6.46 2.28 7.15 0.59 6.34 32
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
4.88 4.05 3.00 2.75 2.46 4.24 2.64 3.10 1.97 1.70
Price to Tangible Book Value (P/TBV)
4.88 4.05 3.00 2.75 2.46 4.24 2.64 10.36 8.05 24.35
Price to Revenue (P/Rev)
4.69 3.98 3.01 2.78 2.60 4.46 3.12 3.94 2.85 6.97
Price to Earnings (P/E)
20.24 15.76 11.51 10.13 8.88 14.79 9.47 15.37 10.56 9.59
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
4.94% 6.35% 8.69% 9.87% 11.26% 6.76% 10.56% 6.51% 9.47% 10.42%
Enterprise Value to Invested Capital (EV/IC)
34.86 15.45 8.02 10.08 8.41 17.67 10.24 3.34 2.06 1.73
Enterprise Value to Revenue (EV/Rev)
3.84 3.21 2.29 1.97 1.75 3.62 2.16 3.81 2.73 6.80
Enterprise Value to EBITDA (EV/EBITDA)
13.14 10.22 6.99 5.82 4.94 11.09 6.15 14.27 9.83 8.22
Enterprise Value to EBIT (EV/EBIT)
13.67 10.57 7.20 5.97 5.06 11.40 6.32 14.87 10.23 8.32
Enterprise Value to NOPAT (EV/NOPAT)
16.72 13.05 9.15 7.61 6.47 12.97 7.20 13.17 9.20 21.42
Enterprise Value to Operating Cash Flow (EV/OCF)
12.00 10.41 8.30 5.84 6.30 11.56 5.44 11.85 7.50 15.69
Enterprise Value to Free Cash Flow (EV/FCFF)
15.18 19.01 17.48 9.15 11.50 14.65 6.10 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.86 -0.81 -0.75 -0.81 -0.84 -0.80 -0.78 -0.42 -0.41 -0.22
Leverage Ratio
1.16 1.12 1.14 1.15 1.14 1.10 1.11 1.12 1.10 1.05
Compound Leverage Factor
1.20 1.23 1.23 1.25 1.27 1.47 1.24 3.00 1.13 1.06
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
20.70 22.08 14.99 13.48 14.96 32.08 23.82 24.91 16.88 27.28
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
6.16 7.13 6.23 6.03 7.51 10.64 12.18 3.72 3.14 3.59
Quick Ratio
5.87 6.85 5.87 5.74 7.23 10.21 11.67 3.28 2.83 3.06
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
4.84 -1.43 -2.58 2.71 -2.96 1.60 8.99 -58 -60 -204
Operating Cash Flow to CapEx
1,633.60% 210.85% 134.74% 3,795.25% 3,242.28% 0.00% 6,943.21% 0.00% 18,357.14% 0.00%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.97 1.00 0.97 0.97 0.95 0.97 0.86 0.77 0.69 0.35
Accounts Receivable Turnover
14.24 15.11 8.25 11.17 13.89 13.62 8.51 9.15 9.33 10.72
Inventory Turnover
4.56 8.35 8.22 9.61 10.06 15.28 15.13 16.26 17.20 11.85
Fixed Asset Turnover
36.20 25.11 21.59 23.50 22.75 24.87 0.00 20.33 23.57 22.91
Accounts Payable Turnover
11.85 6.65 13.52 9.89 12.21 11.29 19.67 19.02 16.67 17.56
Days Sales Outstanding (DSO)
25.63 24.16 44.25 32.68 26.29 26.79 42.87 39.91 39.12 34.05
Days Inventory Outstanding (DIO)
80.13 43.74 44.39 37.97 36.27 23.88 24.12 22.45 21.22 30.79
Days Payable Outstanding (DPO)
30.81 54.85 26.99 36.90 29.89 32.32 18.56 19.19 21.90 20.78
Cash Conversion Cycle (CCC)
74.95 13.04 61.65 33.74 32.66 18.35 48.43 43.17 38.44 44.06
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
6.00 12 17 13 14 14 14 70 78 221
Invested Capital Turnover
8.21 5.91 4.42 5.76 6.72 5.30 4.21 1.49 1.28 0.48
Increase / (Decrease) in Invested Capital
-1.27 4.37 7.27 2.80 7.93 2.18 -3.55 58 64 207
Enterprise Value (EV)
209 182 140 127 117 247 142 235 161 383
Market Capitalization
255 226 183 180 174 304 205 243 168 392
Book Value per Share
$7.70 $8.14 $8.94 $9.53 $10.32 $10.45 $11.08 $11.10 $11.96 $31.76
Tangible Book Value per Share
$7.70 $8.14 $8.94 $9.53 $10.32 $10.45 $11.08 $3.32 $2.93 $2.22
Total Capital
52 56 61 65 71 72 78 78 85 231
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-46 -44 -44 -53 -57 -58 -63 -7.98 -7.21 -9.46
Capital Expenditures (CapEx)
0.49 0.81 0.64 0.30 0.15 -0.74 0.08 -0.03 0.04 -0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-2.24 -1.04 3.71 -1.16 -0.23 2.41 3.12 9.86 7.95 7.42
Debt-free Net Working Capital (DFNWC)
43 42 47 51 56 60 66 17 15 16
Net Working Capital (NWC)
43 42 47 51 56 60 66 17 15 16
Net Nonoperating Expense (NNE)
-0.11 -0.28 -0.28 -0.37 -0.54 -0.44 -0.64 0.04 -1.15 -26
Net Nonoperating Obligations (NNO)
-46 -44 -44 -53 -57 -58 -64 -7.98 -7.21 -9.46
Total Depreciation and Amortization (D&A)
0.15 0.13 0.13 0.15 0.16 0.16 0.18 0.17 0.13 0.10
Debt-free, Cash-free Net Working Capital to Revenue
-4.12% -1.83% 6.09% -1.79% -0.34% 3.54% 4.73% 15.97% 13.50% 13.19%
Debt-free Net Working Capital to Revenue
79.54% 74.18% 76.67% 78.37% 83.38% 87.62% 100.18% 28.06% 24.87% 29.09%
Net Working Capital to Revenue
79.54% 74.18% 76.67% 78.37% 83.38% 87.62% 100.18% 28.06% 24.87% 29.09%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.55 $0.48 $0.74 $0.88 $0.82 $0.62 $0.88 $0.00 $0.80 $3.98
Adjusted Weighted Average Basic Shares Outstanding
6.68M 6.73M 6.70M 6.71M 6.72M 6.73M 6.89M 6.94M 7.05M 7.23M
Adjusted Diluted Earnings per Share
$0.46 $0.41 $0.63 $0.75 $0.71 $0.54 $0.78 $0.00 $0.72 $3.63
Adjusted Weighted Average Diluted Shares Outstanding
7.94M 8.00M 7.90M 7.87M 7.82M 7.82M 7.78M 7.80M 7.77M 7.98M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
6.84M 6.84M 6.85M 6.86M 6.87M 7.03M 7.07M 7.13M 7.27M 9.60M
Normalized Net Operating Profit after Tax (NOPAT)
3.57 2.94 4.69 5.51 5.44 1.76 5.43 3.75 4.46 3.18
Normalized NOPAT Margin
25.40% 21.30% 25.74% 29.60% 33.36% 11.72% 34.17% 25.89% 32.98% 25.58%
Pre Tax Income Margin
32.75% 28.68% 36.43% 41.20% 42.83% 18.68% 49.03% 7.86% 47.18% 262.41%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
39.56% 34.84% 0.00% 22.52% 9.96% 9.47% 0.00% 0.64% 3.69% 7.34%

Frequently Asked Questions About Semler Scientific's Financials

When does Semler Scientific's fiscal year end?

According to the most recent income statement we have on file, Semler Scientific's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Semler Scientific's net income changed over the last 2 years?

Semler Scientific's net income appears to be on an upward trend, with a most recent value of $40.90 million in 2024, rising from $14.33 million in 2022. The previous period was $20.58 million in 2023.

What is Semler Scientific's operating income?
Semler Scientific's total operating income in 2024 was $20.93 million, based on the following breakdown:
  • Total Gross Profit: $51.54 million
  • Total Operating Expenses: $30.60 million
How has Semler Scientific revenue changed over the last 2 years?

Over the last 2 years, Semler Scientific's total revenue changed from $56.69 million in 2022 to $56.29 million in 2024, a change of -0.7%.

How much debt does Semler Scientific have?

Semler Scientific's total liabilities were at $9.08 million at the end of 2024, a 44.8% increase from 2023, and a 29.4% increase since 2022.

How much cash does Semler Scientific have?

In the past 2 years, Semler Scientific's cash and equivalents has ranged from $8.82 million in 2024 to $57.20 million in 2023, and is currently $8.82 million as of their latest financial filing in 2024.

How has Semler Scientific's book value per share changed over the last 2 years?

Over the last 2 years, Semler Scientific's book value per share changed from 8.14 in 2022 to 31.76 in 2024, a change of 290.1%.

Remove Ads


This page (NASDAQ:SMLR) was last updated on 4/15/2025 by MarketBeat.com Staff
From Our Partners